Cost Management of Niraparib in Ovarian Cancer
Author Information
Author(s): Graybill Whitney S, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Haggerty Ashley F, Fabbro Michel, Chan John K, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio
Primary Institution: Medical University of South Carolina
Hypothesis
Does the individualized starting dose of niraparib reduce the costs of managing hematologic adverse events compared to a fixed starting dose?
Conclusion
Using an individualized starting dose of niraparib significantly reduces the cost of managing hematologic adverse events compared to a fixed starting dose.
Supporting Evidence
- The individualized starting dose reduced the total cost of managing hematologic adverse events by 48.1%.
- Thrombocytopenia had the greatest cost reduction of 59.1% with the individualized starting dose.
- The total mean calculated cost per patient was $12,987.71 with the fixed starting dose and $6744.93 with the individualized starting dose.
- Results support the use of individualized dosing in clinical practice for better cost management.
- Patients with lower body weight and platelet counts benefited from the individualized starting dose.
- The study utilized data from a phase III clinical trial to assess cost differences.
- Cost calculations were based on US healthcare costs adjusted to 2020 dollars.
- Findings highlight the economic impact of personalized medicine in cancer treatment.
Takeaway
Using a special dose of a cancer medicine called niraparib can save money when treating side effects related to blood cells compared to using the same dose for everyone.
Methodology
The study analyzed costs associated with grade ≥3 hematologic adverse events from a phase III trial comparing individualized and fixed starting doses of niraparib.
Potential Biases
Potential data entry errors and incomplete reporting in the HCUP database.
Limitations
The small sample size for the individualized starting dose and the reliance on a database that may not capture all costs.
Participant Demographics
Patients with newly diagnosed advanced ovarian cancer who responded to platinum-based chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website